Nocturnal hypertension in diabetes: Potential target of sodium/glucose cotransporter 2 (SGLT2) inhibition.
作者信息
Kario Kazuomi, Weber Michael, Ferrannini Ele
机构信息
Division of Cardiovascular Medicine, Department of Medicine, JMU Center of Excellence, Community Medicine Cardiovascular Research and Development (JCARD), Jichi Medical University School of Medicine (JMU), Shimotsuke, Tochigi, Japan.
Division of Cardiovascular Medicine, Downstate Medical Center, State University of New York, Brooklyn, NY, USA.
出版信息
J Clin Hypertens (Greenwich). 2018 Mar;20(3):424-428. doi: 10.1111/jch.13229. Epub 2018 Feb 19.
Abstract
摘要
相似文献
1
Nocturnal hypertension in diabetes: Potential target of sodium/glucose cotransporter 2 (SGLT2) inhibition.糖尿病中的夜间高血压：钠/葡萄糖协同转运蛋白2（SGLT2）抑制的潜在靶点。
J Clin Hypertens (Greenwich). 2018 Mar;20(3):424-428. doi: 10.1111/jch.13229. Epub 2018 Feb 19.
2
Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors on Cardiovascular and Metabolic Outcomes in Patients Without Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized-Controlled Trials.钠-葡萄糖协同转运蛋白 2（SGLT2）抑制剂对非糖尿病患者心血管和代谢结局的影响：一项随机对照试验的系统评价和荟萃分析。
J Am Heart Assoc. 2021 Feb;10(5):e019463. doi: 10.1161/JAHA.120.019463. Epub 2021 Feb 24.
3
Research digest: SGLT2 inhibition in kidney and liver disease.研究摘要：SGLT2抑制剂在肾脏和肝脏疾病中的应用
Lancet Diabetes Endocrinol. 2019 Jun;7(6):427. doi: 10.1016/S2213-8587(19)30160-3.
4
Cardiovascular Safety, Long-Term Noncardiovascular Safety, and Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Systemic Review and Meta-Analysis With Trial Sequential Analysis.钠-葡萄糖共转运蛋白 2 抑制剂在 2 型糖尿病患者中的心血管安全性、长期非心血管安全性和疗效：系统评价和试验序贯分析。
J Am Heart Assoc. 2018 Jan 20;7(2):e007165. doi: 10.1161/JAHA.117.007165.
5
SGLT2 Inhibitors-A Medical Revelation: Molecular Signaling of Canagliflozin Underlying Hypertension and Vascular Remodeling.钠-葡萄糖协同转运蛋白2抑制剂——一项医学新发现：卡格列净引发高血压和血管重塑的分子信号传导
J Am Heart Assoc. 2022 Aug 2;11(15):e026774. doi: 10.1161/JAHA.122.026774. Epub 2022 Jul 29.
6
SGLT-2 inhibitors in diabetes: a focus on renoprotection.糖尿病中的钠-葡萄糖协同转运蛋白2抑制剂：聚焦肾脏保护作用
Rev Assoc Med Bras (1992). 2020 Jan 13;66Suppl 1(Suppl 1):s17-s24. doi: 10.1590/1806-9282.66.S1.17.
7
The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments.SGLT2 抑制剂治疗 2 型糖尿病的药代动力学和药效学：最新进展。
Expert Opin Drug Metab Toxicol. 2018 Dec;14(12):1287-1302. doi: 10.1080/17425255.2018.1551877. Epub 2018 Nov 29.
8
Renoprotective effects of sodium-glucose cotransporter-2 inhibitors.钠-葡萄糖共转运蛋白 2 抑制剂的肾脏保护作用。
Kidney Int. 2018 Jul;94(1):26-39. doi: 10.1016/j.kint.2017.12.027. Epub 2018 May 5.
9
Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure.钠-葡萄糖协同转运蛋白2抑制剂对血压的影响。
Vasc Health Risk Manag. 2016 Oct 27;12:393-405. doi: 10.2147/VHRM.S111991. eCollection 2016.
10
[In patients with type 2 diabetes and diabetic nephropathy with albuminuria, what is the effect of SGLT2 inhibitor canagliflozin on renal and cardiovascular outcomes?].[在2型糖尿病合并糖尿病肾病伴蛋白尿的患者中，钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂卡格列净对肾脏和心血管结局有何影响？]
Rev Med Interne. 2020 Jan;41(1):67-68. doi: 10.1016/j.revmed.2019.11.004. Epub 2019 Dec 4.
引用本文的文献
1
Obstructive sleep apnea -related hypertension: a review of the literature and clinical management strategy.阻塞性睡眠呼吸暂停相关高血压：文献回顾与临床管理策略。
Hypertens Res. 2024 Nov;47(11):3085-3098. doi: 10.1038/s41440-024-01852-y. Epub 2024 Aug 29.
2
A Narrative Review of the Association of Obstructive Sleep Apnea with Hypertension: How to Treat Both When They Coexist?阻塞性睡眠呼吸暂停与高血压关联的叙述性综述：二者并存时如何进行治疗？
J Clin Med. 2023 Jun 20;12(12):4144. doi: 10.3390/jcm12124144.
3
Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism.钠-葡萄糖协同转运蛋白2抑制剂对水和钠代谢的影响
Front Pharmacol. 2022 Feb 23;13:800490. doi: 10.3389/fphar.2022.800490. eCollection 2022.
4
Safety and efficacy of empagliflozin in elderly Japanese patients with type 2 diabetes mellitus: A post hoc analysis of data from the SACRA study.恩格列净在老年 2 型糖尿病日本患者中的安全性和疗效：来自 SACRA 研究的数据事后分析。
J Clin Hypertens (Greenwich). 2021 Apr;23(4):860-869. doi: 10.1111/jch.14131. Epub 2020 Dec 16.
5
Expert panel consensus recommendations for ambulatory blood pressure monitoring in Asia: The HOPE Asia Network.亚洲动态血压监测专家共识推荐意见：HOPE 亚洲网络。
J Clin Hypertens (Greenwich). 2019 Sep;21(9):1250-1283. doi: 10.1111/jch.13652.
6
Blood Pressure Lowering and Sodium-Glucose Co-transporter 2 Inhibitors (SGLT2is): More Than Osmotic Diuresis.降压与钠-葡萄糖共转运蛋白 2 抑制剂（SGLT2is）：不仅仅是渗透性利尿。
Curr Hypertens Rep. 2019 Feb 12;21(2):12. doi: 10.1007/s11906-019-0920-4.
7
Effect of canagliflozin on nocturnal home blood pressure in Japanese patients with type 2 diabetes mellitus: The SHIFT-J study.卡格列净对日本 2 型糖尿病患者夜间家庭血压的影响：SHIFT-J 研究。
J Clin Hypertens (Greenwich). 2018 Oct;20(10):1527-1535. doi: 10.1111/jch.13367. Epub 2018 Sep 23.
本文引用的文献
1
Global Impact of 2017 American Heart Association/American College of Cardiology Hypertension Guidelines: A Perspective From Japan.2017年美国心脏协会/美国心脏病学会高血压指南的全球影响：来自日本的观点
Circulation. 2018 Feb 6;137(6):543-545. doi: 10.1161/CIRCULATIONAHA.117.032851.
2
Development of a New ICT-Based Multisensor Blood Pressure Monitoring System for Use in Hemodynamic Biomarker-Initiated Anticipation Medicine for Cardiovascular Disease: The National IMPACT Program Project.基于新 ICT 的多传感器血压监测系统的开发，用于心血管疾病的血流动力学生物标志物启动的预期医学：国家 IMPACT 计划项目。
Prog Cardiovasc Dis. 2017 Nov-Dec;60(3):435-449. doi: 10.1016/j.pcad.2017.10.002. Epub 2017 Nov 3.
3
Hemoglobin A1c and C-reactive protein are independently associated with blunted nocturnal blood pressure dipping in obesity-related prediabetes.糖化血红蛋白 A1c 和 C 反应蛋白与肥胖相关的糖尿病前期夜间血压下降减弱独立相关。
Hypertens Res. 2018 Jan;41(1):33-38. doi: 10.1038/hr.2017.82. Epub 2017 Oct 26.
4
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.卡格列净与 2 型糖尿病的心血管和肾脏事件。
N Engl J Med. 2017 Aug 17;377(7):644-657. doi: 10.1056/NEJMoa1611925. Epub 2017 Jun 12.
5
Effects of Sodium-Glucose Cotransporter 2 Inhibitors on 24-Hour Ambulatory Blood Pressure: A Systematic Review and Meta-Analysis.钠-葡萄糖协同转运蛋白2抑制剂对24小时动态血压的影响：一项系统评价和荟萃分析。
J Am Heart Assoc. 2017 May 18;6(5):e005686. doi: 10.1161/JAHA.117.005686.
6
Sodium-Glucose Co-transporters and Their Inhibition: Clinical Physiology.钠-葡萄糖协同转运蛋白及其抑制剂：临床生理学。
Cell Metab. 2017 Jul 5;26(1):27-38. doi: 10.1016/j.cmet.2017.04.011. Epub 2017 May 11.
7
Cardioprotective effects of SGLT2 inhibitors are possibly associated with normalization of the circadian rhythm of blood pressure.钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂的心脏保护作用可能与血压昼夜节律的正常化有关。
Hypertens Res. 2017 Jun;40(6):535-540. doi: 10.1038/hr.2016.193. Epub 2017 Jan 19.
8
Riser Pattern Is a Novel Predictor of Adverse Events in Heart Failure Patients With Preserved Ejection Fraction.上升型模式是射血分数保留的心力衰竭患者不良事件的一种新型预测指标。
Circ J. 2017 Jan 25;81(2):220-226. doi: 10.1253/circj.CJ-16-0740. Epub 2016 Dec 23.
9
CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.在 EMPA-REG OUTCOME 试验中对 CV 进行保护：“节俭型底物”假说。
Diabetes Care. 2016 Jul;39(7):1108-14. doi: 10.2337/dc16-0330.
10
Evidence and Perspectives on the 24-hour Management of Hypertension: Hemodynamic Biomarker-Initiated 'Anticipation Medicine' for Zero Cardiovascular Event.高血压 24 小时管理的证据与展望：零心血管事件的血流动力学生物标志物触发“预见医学”
Prog Cardiovasc Dis. 2016 Nov-Dec;59(3):262-281. doi: 10.1016/j.pcad.2016.04.001. Epub 2016 Apr 11.
Zotero 插件